In re: Rotavirus Vaccines Antitrust Litigation v. ( 2022 )


Menu:
  •                                     PRECEDENTIAL
    UNITED STATES COURT OF APPEALS
    FOR THE THIRD CIRCUIT
    _____________
    No. 20-3460
    _____________
    In re: ROTAVIRUS VACCINES ANTITRUST
    LITIGATION
    SUGARTOWN PEDIATRICS, LLC;
    SCHWARTZ PEDIATRICS SC;
    MARGIOTTI & KROLL PEDIATRICS, PC
    v.
    MERCK SHARP & DOHME CORP.,
    Appellant
    _____________
    On Appeal from the United States District Court
    for the Eastern District of Pennsylvania
    (D.C. No. 2-18-cv-01734)
    District Judge: Honorable J. Curtis Joyner
    _____________
    Argued on September 24, 2021
    Before: CHAGARES, Chief Judge, HARDIMAN, and
    MATEY, Circuit Judges
    (Filed: March 21, 2022)
    Ashley E. Bass [argued]
    Andrew D. Lazerow
    Mark W. Mosier
    Covington & Burling
    850 10th Street, N.W.
    One City Center
    Washington, DC 20001
    Lisa C. Dykstra
    Morgan Lewis & Bockius
    1701 Market Street
    Philadelphia, PA 19103
    Counsel for Appellant
    Leonardo Chingcuanco
    Daniel H. Silverman [argued]
    Daniel A. Small
    Cohen Milstein
    1100 New York Avenue, N.W.
    West Tower, Suite 500
    Washington, DC 20005
    Gary L. Azorsky
    Cohen Milstein
    1717 Arch Street
    3 Logan Square, Suite 3610
    Philadelphia, PA 19103
    Eric L. Cramer
    David A. Langer
    2
    Daniel J. Walker
    Berger Montague
    1818 Market Street
    Suite 3600
    Philadelphia, PA 19103
    Counsel for Appellees
    ________________
    OPINION OF THE COURT
    ________________
    HARDIMAN, Circuit Judge.
    This appeal comes to us from an order denying a motion
    to compel arbitration. Appellant Merck contends the District
    Court should have compelled Sugartown Pediatrics, Schwartz
    Pediatrics, and Margiotti & Kroll Pediatrics (the Pediatricians)
    to arbitrate their claim that Merck’s vaccine bundling scheme
    was anticompetitive. We agree. We will reverse and remand
    for the District Court to grant Merck’s motion to compel
    arbitration.
    I
    This case involves two types of contracts. Both are part
    of Merck’s loyalty program, whereby medical practices
    receive discounts if they buy sufficient vaccine quantities from
    Merck. The first type of contract is between Merck and
    Physician Buying Groups (PBGs). These loyalty contracts
    entitle PBG members to discounts if they buy a large enough
    percentage of their vaccines from Merck. The loyalty contracts
    also include an arbitration provision. The second type of
    3
    contract is between PBGs and medical practices. These
    membership contracts give medical practices discounts on
    Merck vaccines for enrolling in PBGs. PBGs thus form the
    bridge between medical practices and Merck, contracting with
    both Merck and medical practices. They are middlemen in all
    but one relevant sense: PBGs never possess the vaccines.
    Medical practices buy their vaccines directly from Merck, but
    they receive discounts for belonging to a PBG.
    Though they were members of PBGs that contracted
    with Merck, 1 the Pediatricians never signed contracts
    containing an arbitration clause. So the Pediatricians filed
    federal suits alleging Merck’s vaccine bundling program was
    anticompetitive. Merck responded with a motion to compel
    arbitration based on the arbitration clause contained in its
    loyalty contracts with the PBGs, which the District Court
    denied under the summary judgment standard. In re Rotavirus
    Vaccines Antitrust Litig. (Rotavirus I), 
    362 F. Supp. 3d 255
    ,
    261, 264–65 (E.D. Pa. 2019). The first time this case came
    before us, we vacated the order of the District Court, holding
    that it should have allowed discovery on arbitrability. In re
    Rotavirus Vaccines Antitrust Litig. (Rotavirus II), 789 F.
    App’x 934, 938 (3d Cir. 2019).
    After the parties conducted discovery, Merck renewed
    its motion to compel arbitration and the Pediatricians cross-
    moved for summary judgment on arbitrability. In re Rotavirus
    Vaccines Antitrust Litig. (Rotavirus III), 
    2020 WL 6828123
    , at
    *1 (E.D. Pa. Nov. 20, 2020). The District Court once again
    1
    Schwartz was a member of Children’s Community
    Physicians Association Purchasing Partners (CCPAPP).
    Sugartown and Margiotti & Kroll were members of Main
    Street Vaccines (MSV).
    4
    denied Merck’s motion to compel arbitration and granted
    summary judgment for the Pediatricians. Id. at *15. The Court
    concluded, as relevant here, that the Pediatricians were not
    bound under an agency theory because they had not authorized
    the PBGs to enter into arbitration agreements. Id. at *13–14.
    This appeal followed.
    II
    The District Court had jurisdiction over the
    Pediatricians’ antitrust claims. See 
    28 U.S.C. § 1331
    ; 
    15 U.S.C. § 4
    . We have jurisdiction to review the order denying a
    motion to compel arbitration under 
    9 U.S.C. § 16
    (a)(1)(B). For
    jurisdictional purposes, motions to compel arbitration and
    motions for summary judgment on arbitrability—both of
    which are at issue in this appeal—are equivalent. See Bacon v.
    Avis Budget Grp., Inc., 
    959 F.3d 590
    , 598–99 & n.4 (3d Cir.
    2020).
    Our review of the District Court’s decision, including
    its legal conclusion that the PBGs were not the Pediatricians’
    agents, is plenary. O’Hanlon v. Uber Techs., Inc., 
    990 F.3d 757
    , 766 n.5 (3d Cir. 2021). We apply the summary judgment
    standard, so “[t]he party opposing arbitration is given the
    benefit of all reasonable doubts and inferences that may arise.”
    Griswold v. Coventry First LLC, 
    762 F.3d 264
    , 270 (3d Cir.
    2014) (quoting Kaneff v. Del. Title Loans, Inc., 
    587 F.3d 616
    ,
    620 (3d Cir. 2009)). No material facts are in dispute.
    III
    The Federal Arbitration Act (FAA) “‘declare[s] a
    national policy favoring arbitration’ of claims that parties
    contract to settle in that manner.” Preston v. Ferrer, 
    552 U.S.
                                  5
    346, 353 (2008) (quoting Southland Corp. v. Keating, 
    465 U.S. 1
    , 10 (1984)). But courts must be sure that the parties have
    agreed to arbitrate their claims. After all, “[a]rbitration is
    strictly a matter of consent.” Lamps Plus, Inc. v. Varela, 
    139 S. Ct. 1407
    , 1415 (2019) (quoting Granite Rock Co. v.
    Teamsters, 
    561 U.S. 287
    , 299 (2010)).
    Nonsignatories will be bound to an arbitration
    agreement only when “traditional principles of contract and
    agency law” so require. Hamilton Park Health Care Ctr. Ltd.
    v. 1199 SEIU United Healthcare Workers E., 
    817 F.3d 857
    ,
    864 (3d Cir. 2016) (quoting E.I. DuPont de Nemours & Co. v.
    Rhone Poulenc Fiber & Resin Intermediates, S.A.S., 
    269 F.3d 187
    , 194 (3d Cir. 2001)). Pennsylvania contract law recognizes
    “five theories for binding nonsignatories to arbitration
    agreements,” including agency. Allstate Settlement Corp. v.
    Rapid Settlements, Ltd., 
    559 F.3d 164
    , 170 (3d Cir. 2009)
    (quoting Trippe Mfg. Co. v. Niles Audio Corp., 
    401 F.3d 529
    ,
    532 (3d Cir. 2005)). A principal will be bound by his agent’s
    acts—including an agreement to arbitrate—if the agent has
    actual or apparent authority. Wisler v. Manor Care of
    Lancaster PA, LLC, 
    124 A.3d 317
    , 323 (Pa. Super. Ct. 2015).
    A
    Merck argues that the Pediatricians granted the PBGs
    actual authority to consent to the arbitration clauses on the
    Pediatricians’ behalf. We agree, at least as to Schwartz
    Pediatrics.
    Under Pennsylvania law, “the three basic elements of
    agency are: [1] the manifestation by the principal that the agent
    shall act for him, [2] the agent’s acceptance of the
    undertaking[,] and [3] the understanding of the parties that the
    6
    principal is to be in control of the undertaking.”
    Commonwealth v. Britton, 
    229 A.3d 590
    , 598 (Pa. 2020)
    (quoting Basile v. H & R Block, Inc., 
    761 A.2d 1115
    , 1120 (Pa.
    2000)).
    Schwartz’s contract with its PBG satisfies the first two
    prongs of this test. Its 2016 PBG membership contract made
    the PBG Schwartz’s “non-exclusive agent to arrange for the
    purchase of goods and services,” Rotavirus III, 
    2020 WL 6828123
    , at *9; and a previous version of the membership
    agreement, effective in 1999, contained a similarly explicit
    provision, see App. 2412 (“Each Limited Partner hereby
    appoints the Partnership as its agent for the purpose of
    negotiating and entering into Vendor Arrangements, and the
    Partnership hereby accepts such appointment.”). By agreeing
    to these terms, Schwartz manifested an intent to have the PBG
    act for it, and the PBG accepted that responsibility. The PBG
    acted on this authority in 2012 by executing the loyalty
    contract with Merck that included the arbitration clause. Thus,
    the first two elements of the agency test are satisfied here for
    Schwartz.
    Accordingly, the only remaining question is whether
    Schwartz exercised sufficient control over its PBG to meet the
    control requirement of the Pennsylvania agency test. See
    Britton, 229 A.3d at 598.
    1
    Although the parties dispute how it applies here,
    Pennsylvania agency law is clear on the control requirement.
    “[A]n agency relationship is established only when the
    principal exercises control over the action at hand.” Id.; see
    also Menichini v. Grant, 
    995 F.2d 1224
    , 1233 n.14 (3d Cir.
    7
    1993). The principal can control the agent by “prescribing what
    the agent shall or shall not do before the agent acts,” or by
    directly controlling the agent during performance. Smalich v.
    Westfall, 
    269 A.2d 476
    , 480–81 (Pa. 1970) (quoting
    Restatement (Second) of Agency § 14 cmt. a (Am. L. Inst.
    1958)). The question in this appeal is whether Schwartz—the
    alleged principal—had the right or ability to control its PBG,
    the alleged agent. See Commonwealth v. Minds Coal Mining
    Corp., 
    60 A.2d 14
    , 20 (Pa. 1948) (“[C]ontrol over the means
    of performance is not the test of agency.”).
    Here, Schwartz exercised control over its PBG by
    circumscribing the PBG’s authority. Schwartz made the PBG
    its agent only for the limited purpose of vaccine purchases.
    Rotavirus III, 
    2020 WL 6828123
    , at *9 (2016 CCPAPP
    membership contract, limiting agency to “the purchase of
    goods and services as set forth herein”); App. 2412 (1999
    membership contract “appoint[ing] the [PBG] as [Schwartz’s]
    agent for the purpose of negotiating and entering into Vendor
    Arrangements”). Thus, Schwartz simultaneously demonstrated
    its intent to create an agency relationship and exercised control
    over the scope of the PBG’s agency by contract.
    The Pediatricians counter that this case is like Basile,
    where the Pennsylvania Supreme Court held that no agency
    relationship exists where the alleged agent merely presents an
    opportunity to the alleged principal. Basile, 761 A.2d at 1121.
    In Basile, H & R Block offered its customers the opportunity
    to obtain loans from a third party. Id. at 1117. The court held
    that H & R Block’s “mere facilitation” of the loan did not
    create an agency relationship. Id. at 1121. “Rather, the action
    [giving rise to the agency relationship] must be a matter of
    consequence or trust, such as the ability to actually bind the
    principal or alter the principal’s legal relations.” Id. (emphasis
    8
    omitted). Because such action was lacking, there was no
    agency relationship.
    The Pediatricians’ reliance on Basile is inapt. In that
    case, the customers did not contractually designate H & R
    Block as their agent. So the court looked to the parties’ conduct
    to determine whether an agency relationship existed. In doing
    so, the Basile court distinguished “mere facilitation” of an
    opportunity from an agency relationship. Id. Unlike in Basile,
    here Schwartz signed a membership contract that expressly
    designated the PBG as its purchasing agent. Because of the
    explicit authority delegated by that contract, Merck need not
    rely on the relationship between the parties to establish an
    agency relationship.
    2
    The Pediatricians also argue that the PBGs were not
    acting as their agents because they did not notify the
    Pediatricians about the arbitration clauses. The Pediatricians
    claim that the PBGs had no authority to agree to “undisclosed
    terms” with Merck. This argument also rests on a flawed
    analogy to Basile.
    To exercise the requisite degree of control, the principal
    must be adequately informed of the agent’s actions.
    Accordingly, the agent has a fiduciary duty to keep the
    principal informed of “all relevant information.” Id. at 1120.
    Because of the agent’s duty to disclose, the agent’s knowledge
    is imputed to the principal. W.C.A.B. v. Evening Bulletin, 
    445 A.2d 1190
    , 1192 (Pa. 1982); see also Restatement (Third) of
    Agency § 5.03 (Am. L. Inst. 2006) (“[N]otice of a fact that an
    agent knows or has reason to know is imputed to the principal
    9
    if knowledge of the fact is material to the agent’s duties to the
    principal.”).
    But what if the agent does not fulfill its fiduciary duties?
    An agency relationship still exists even if the agent fails to
    notify the principal of all relevant information. See
    Restatement (Third) of Agency § 5.03 cmt. b (Am. L. Inst.
    2006) (“A principal may not rebut the imputation of an agent’s
    notice of a fact by establishing that the agent kept silent.”). Put
    more simply, an agent might fail to perform his duty but remain
    the principal’s agent. In such a case, the proper recourse for the
    principal is an action against the agent for breach of fiduciary
    duty or malpractice; but the principal will nevertheless be
    bound by the agent’s actions. See, e.g., Patel v. Mericle Com.
    Real Est. Grp., 
    2017 WL 11144107
    , at *4 (M.D. Pa. 2017)
    (allowing malpractice and breach of fiduciary duty claims
    against an agent to proceed based on the agent’s failure to
    disclose material information).
    Here, the Pediatricians claim ignorance of the
    arbitration clause. Based on that fact, the District Court
    concluded that the Pediatricians were not bound by the
    arbitration clause because the PBGs were not acting within the
    scope of their agency authority when they agreed to the
    arbitration clauses. Rotavirus III, 
    2020 WL 6828123
    , at *14
    (“[W]e are constrained to conclude that the member practices[]
    granted only very limited authority to their PBGs to enter into
    those terms and conditions of the Merck contracts which had
    been communicated to them.”).
    The District Court’s conclusion does not follow from its
    premise. The Pediatricians’ lack of notice is relevant to the
    adequacy of the PBGs’ performance as agents, but it does not
    answer the antecedent question of whether an agency
    10
    relationship existed. See Restatement (Third) of Agency § 5.03
    cmt. b (Am. L. Inst. 2006). Unlike in Basile, where there was
    no contract conferring agency on H & R Block, the contracts
    between the PBGs and the Pediatricians clearly established the
    agency relationship, and the authority to agree to an arbitration
    clause is part and parcel of the agency relationship in
    commercial contexts. See Dye v. Tamko Bldg. Prods., Inc., 
    908 F.3d 675
    , 684–86 (11th Cir. 2018); see also HealthplanCRM,
    LLC v. AvMed, Inc., 
    458 F. Supp. 3d 308
    , 335 (W.D. Pa. 2020)
    (noting that Dye “provides persuasive guidance consistent with
    Pennsylvania law”). Subsequent actions, such as the PBGs’
    alleged failure to notify, go only to whether the PBGs fulfilled
    their fiduciary duties. Even if the PBGs breached their duties
    to the Pediatricians, that does not release the Pediatricians from
    their obligations under the arbitration clause. If this case were
    more like Basile, and there was no explicit contract conferring
    agency on the PBGs, then the Pediatricians would be correct—
    we would look to the parties’ conduct to determine the
    existence and scope of their agency relationship. But here, a
    written contract created an agency relationship that included
    the implied authority to accept an arbitration provision.
    For these reasons, Schwartz Pediatrics is bound to
    arbitrate because it granted actual authority to its PBG.
    B
    Sugartown and Margiotti & Kroll’s contract with their
    PBG would have established actual authority had it been
    signed earlier. That contract authorized the PBG to “act as a
    purchasing agent for [PBG members] to enter into contracts
    with third-party vendors to furnish goods or services to [PBG
    members].” Rotavirus III, 
    2020 WL 6828123
    , at *11. But that
    language was not inserted into the membership contract until
    11
    2019, years after the PBG executed its 2012 loyalty contract
    with Merck. The earlier contracts between the two
    Pediatricians and their PBG were less explicit about the PBG’s
    agency but still contained provisions from which agency could
    be inferred. See App. 2347 (stating that the Pediatricians
    “accept[] the conditions and terms offered in the [PBG-Merck]
    contract” and wish to “participate”); see also App. 2224–25
    (testimony by MSV president that MSV acts as members’
    “limited agent” and has “always negotiated the contracts on
    behalf of [its] members”). In any event, we need not decide
    whether those earlier contracts sufficed to establish actual
    agency authority because, at a minimum, the PBG had apparent
    authority to act for Sugartown and Margiotti & Kroll.
    An agent has apparent authority if “the principal, by
    word or conduct, causes people with whom the alleged agent
    deals to believe that the principal has granted the agent
    authority to act.” Wisler, 124 A.3d at 324 (quoting Walton v.
    Johnson, 
    66 A.3d 782
    , 786 (Pa. Super. Ct. 2013)). In
    Pennsylvania, “apparent authority [may] be established with a
    showing of: (1) limited authority given to the agent by the
    principal; and (2) conduct of the agent which demonstrates to
    the third-party the agent’s apparent authority to bind the
    principal.” Leidigh v. Reading Plaza Gen., Inc., 
    636 A.2d 666
    ,
    667–68 (Pa. Super. Ct. 1994) (citation omitted).
    Both prongs of the test for apparent authority are met
    here. The District Court found “the member practices[] granted
    only very limited authority to their PBGs.” Rotavirus III, 
    2020 WL 6828123
    , at *14. Testimony in the District Court
    confirmed that Sugartown and Margiotti & Kroll’s PBG acted
    on their behalf. See, e.g., id. at *9 (describing testimony by
    MSV’s president that “if a practice was enrolling in the [MSV]
    program through completion of their Enrollment
    12
    Form/Membership Agreement, they were also enrolling into
    the contract which [MSV] had with Merck and agreeing that
    they would abide by the terms and conditions of this contract”);
    App. 2224–25 (testimony by MSV’s president that MSV acts
    as members’ “limited agent” and has “always negotiated the
    contracts on behalf of [its] members”). At a minimum, this
    testimony justified the District Court’s finding that the
    Pediatricians delegated “very limited authority” to their PBGs.
    Rotavirus III, 
    2020 WL 6828123
    , at *14.
    So we turn to the second prong of the test: the conduct
    of the agent. Pennsylvania law tilts in favor of finding that an
    agent has apparent authority. Third parties dealing with an
    agent need only exercise “reasonable diligence to ascertain the
    agent’s authority.” Bolus v. United Penn Bank, 
    525 A.2d 1215
    ,
    1222 (Pa. Super. Ct. 1987). Moreover, “[a]n admitted agent is
    presumed to be acting within the scope of his authority where
    the act is legal and the third party has no notice of the
    limitations on the agent’s authority.” Id. at 1222.
    Here, Merck was justified in believing that the PBGs
    were the Pediatricians’ agents because the PBGs represented
    themselves as agents in their contracts with Merck. App. 2141
    (Merck-CCPAPP contract, warranting that CCPAPP had “the
    authority of the [Pediatricians] to participate in this
    Agreement”); App. 2157 (Merck-MSV contract with identical
    language). Additionally, the Merck-PBG contracts required
    each PBG to meet the federal definition of a “group purchasing
    organization.” App. 2145 (Merck-CCPAPP contract); App.
    2161     (Merck-MSV        contract).    “Group     purchasing
    organization” is defined by federal regulation as “an entity
    authorized to act as a purchasing agent” for medical providers.
    
    42 C.F.R. § 1001.952
    (j)(2). By purchasing vaccines at the rates
    specified in the Merck-PBG contracts, the Pediatricians
    13
    confirmed the impression that the PBGs were acting as their
    agents. Thus, Merck had reason to believe the PBGs were the
    Pediatricians’ agents.
    The Pediatricians’ best argument to the contrary is
    based on a supposed concession by Merck. Merck represented
    to the District Court that, until the Pediatricians submitted their
    contracts with the PBGs, “Merck did not have sufficient
    information about the nature of the relationship between the
    PBGs and their members to assert that the PBGs acted as
    agents for the members with respect to Merck’s contracts.”
    App. 124 n.6. Such a concession would defeat an apparent
    authority theory because Merck could not have believed the
    PBGs were the Pediatricians’ agents if Merck did not know
    about the “nature of the relationship between the PBGs and [the
    Pediatricians].” 
    Id.
    Merck claims this footnote did not concede anything
    substantive; it merely recognized a procedural hurdle.
    Specifically, Merck explains it could not prove an agency
    relationship based solely on the Pediatricians’ complaint and
    needed the Pediatricians to incorporate the agreements into the
    complaint, which they eventually did. Merck’s explanation is
    plausible since the Pediatricians’ complaint devotes only a few
    paragraphs to their relationship with their PBGs. However,
    Merck’s District Court briefing states that “Merck did not have
    sufficient information,” not just that the Pediatricians’
    complaint lacked sufficient information. 
    Id.
     So even if we do
    not fully accept Merck’s explanation, Merck knew something
    about the “nature” of the PBG-Pediatrician relationship
    because of (1) the PBGs’ contractual representations that they
    were the Pediatricians’ agents and (2) the Pediatricians’
    subsequent purchases of discounted vaccines. That gave Merck
    sufficient reason to believe that the PBGs were the
    14
    Pediatricians’ agents, even if it never saw the PBG-Pediatrician
    contracts before this litigation.
    Because both prongs of the apparent authority test are
    satisfied here, Sugartown and Margiotti & Kroll must arbitrate
    their disputes with Merck.
    C
    In a final attempt to avoid arbitration, the Pediatricians
    argue that the arbitration clause’s language does not
    encompass them or their claims. The clause reads: “Any
    controversy, claim or dispute arising out of or relating to the
    performance, construction, interpretation or enforcement of
    this Agreement shall, if not resolved through negotiations
    between the parties, be submitted to mandatory binding
    arbitration pursuant to the Federal Arbitration Act, 9 U.S.C.
    Sec. 1, et. seq.” Rotavirus III, 
    2020 WL 6828123
    , at *2.
    1
    The Pediatricians insist their antitrust claims against
    Merck do not “arise out of or relate to” the contracts between
    Merck and the PBGs. Ped. Br. 25–26. Pennsylvania law
    suggests otherwise. When confronted with an arbitration
    clause nearly identical to this one—with the same “arising out
    of or relating to” language—the Pennsylvania Supreme Court
    concluded that it was framed in the “broadest conceivable
    language,” and inferred “that the parties intended the scope of
    the submission to be unlimited.” Borough of Ambridge Water
    Auth. v. Columbia, 
    328 A.2d 498
    , 501 (Pa. 1974); see also
    Battaglia v. McKendry, 
    233 F.3d 720
    , 727 (3d Cir. 2000)
    (“[W]hen phrases such as ‘arising under’ and ‘arising out of’
    15
    appear in arbitration provisions, they are normally given broad
    construction.”).
    The Pediatricians rely on a case where a more limited
    arbitration clause was at issue. See CardioNet, Inc. v. Cigna
    Health Corp., 
    751 F.3d 165
    , 173–74 (3d Cir. 2014) (“[O]nly
    those disputes ‘regarding the performance or interpretation of
    the Agreement’ must be arbitrated.” (emphasis added)). In
    CardioNet, we held that the arbitration agreement did not cover
    the plaintiffs’ claims. Id. at 179. But in doing so, we
    distinguished a case where an “undisputedly broader”
    arbitration clause was at issue. Id. at 176 (citing Sweet Dreams
    Unlimited, Inc. v. Dial-A-Mattress Int’l, Ltd., 
    1 F.3d 639
    , 642–
    43 (7th Cir. 1993)). That broader clause required arbitration for
    disputes “arising out of” the contract—the same language
    contained in the arbitration clause at issue here. Sweet Dreams,
    
    1 F.3d at 642
    . So CardioNet undermines the Pediatricians’
    arguments.
    For these reasons, we hold that the Pediatricians’
    antitrust claims are covered by the arbitration clause.
    2
    The Pediatricians also claim they are not “parties”
    within the meaning of the contractual language. We disagree.
    First, it is not clear that the scope of the arbitration provision is
    limited to the “parties.” The portion of the clause which
    mentions “the parties” applies only to pre-arbitration
    negotiations: “Any controversy . . . arising out of or relating to
    . . . this Agreement shall, if not resolved through negotiations
    between the parties [be arbitrated].” Rotavirus III, 
    2020 WL 6828123
    , at *2 (emphasis added). The operative provision of
    the arbitration clause, on the other hand, is not limited to “the
    16
    parties.” See 
    id.
     (requiring arbitration of “[a]ny controversy,
    claim or dispute arising out of or relating to [the contract]”).
    And even if the Pediatricians were right that the
    arbitration provision is limited to “the parties,” they would still
    be covered under agency principles. The PBGs were acting as
    their agents, who stand “in the shoes” of their principals,
    including when they “alter the legal relations between the
    principal and third persons.” Tribune-Review Publ’g Co. v.
    Westmoreland Cnty. Hous. Auth., 
    833 A.2d 112
    , 120 (Pa.
    2003) (cleaned up). When the PBGs signed the agreement in
    their capacity as agents, they bound the Pediatricians.
    For these two independently sufficient reasons, we hold
    that the Pediatricians are covered by the arbitration provision.
    *      *       *
    The District Court erred when it denied Merck’s motion
    to compel arbitration. Schwartz Pediatrics made the PBG its
    agent by contract, then the PBG used its authority to bind
    Schwartz to an arbitration clause. Sugartown and Margiotti &
    Kroll must arbitrate because their PBG had apparent authority
    to bind them to the arbitration clause with Merck. We will
    reverse the order of the District Court and remand with the
    instruction that the Court grant Merck’s motion to compel
    arbitration.
    17